Scarica l'app Stockscreener
698.25
2.05%
-14.62
Pre-mercato:
606.00
-92.25
-13.21%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$712.87
Aprire:
$712.69
Volume 24 ore:
696.15K
Relative Volume:
1.01
Capitalizzazione di mercato:
$73.20B
Reddito:
$14.92B
Utile/perdita netta:
$4.42B
Rapporto P/E:
17.01
EPS:
41.0422
Flusso di cassa netto:
$3.79B
1 W Prestazione:
-2.33%
1M Prestazione:
-7.39%
6M Prestazione:
+0.68%
1 anno Prestazione:
+19.36%
Intervallo 1D:
$693.70
$717.88
Intervallo di 1 settimana:
$693.70
$730.59
Portata 52W:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
698.25 | 74.74B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
436.95 | 114.32B | 12.34B | 4.34B | 3.71B | 16.87 |
ARGX
Argen X Se Adr
|
799.32 | 51.13B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.98 | 39.18B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
145.66 | 31.78B | 742.00K | -1.37B | -1.07B | -7.0731 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-31 | Ripresa | Piper Sandler | Overweight |
| 2026-03-06 | Iniziato | Barclays | Overweight |
| 2026-01-07 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2025-12-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Iniziato | HSBC Securities | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Leerink Partners Reiterates "Market Perform" Rating for Regeneron Pharmaceuticals (NASDAQ:REGN) - MarketBeat
Regeneron Shares Tumble Premarket After Fianlimab Study Failure - WSJ
Regeneron faces Wall Street downgrades after high-profile melanoma drug fails to beat Merck's Keytruda - Proactive financial news
Regeneron (REGN) Stock Drops 11% as Melanoma Drug Fails to Topple Merck’s Keytruda - CoinCentral
UnitedHealth, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
S&P 500 Futures Fall in Premarket Trading; Victory Capital, Regeneron Pharmaceuticals Lag - Barron's
Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck’s Keytruda - Barron's
Rare Disease Therapeutics Market 2025-2033 | Market Growth - openPR.com
Regeneron misses again as melanoma combo bows to Merck’s Keytruda in Phase 3 - BioSpace
Regeneron partners with Parabilis for $125m upfront deal By Investing.com - Investing.com Canada
Regeneron Pharmaceuticals and Parabilis Medicines Announce $125 Million Collaboration to Develop Antibody-Helicon™ Conjugates - Quiver Quantitative
Regeneron (REGN) Downgraded Amidst Growth Concerns - GuruFocus
Regeneron pursues up to $2.2B in Helicon milestones on 'undruggable' diseases - Stock Titan
Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas - Business Wire
Why Is Regeneron Stock Sinking Monday? - Benzinga
Cantor Fitzgerald Adjusts PT on Regeneron Pharmaceuticals to $785 From $800, Keeps Overweight Rating - marketscreener.com
Regeneron slides after melanoma study misses key endpoint (REGN) - Yahoo Finance
Truist cuts Regeneron stock price target on LAG-3 trial miss - Investing.com Canada
RBC Capital lowers Regeneron stock price target on fianlimab trial miss - Investing.com Canada
BMO Capital Adjusts PT on Regeneron Pharmaceuticals to $730 From $900, Maintains Outperform Rating - Moomoo
Regeneron Sinks After Late-Stage Melanoma Trial Failure - Bloomberg.com
Regeneron drops after skin cancer treatment misses late-stage trial goal - Reuters
Wells Fargo Adjusts PT on Regeneron Pharmaceuticals to $700 From $800, Maintains Equalweight Rating - marketscreener.com
Citigroup Downgrades Regeneron Pharmaceuticals to Neutral From Buy, Adjusts PT to $700 From $900 - Moomoo
Why is Regeneron Pharmaceuticals stock plunging today? By Investing.com - Investing.com Canada
Analyst recommendations: Applied Materials, Deckers Outdoor, Regeneron Pharmaceuticals, Ciena Corp… - marketscreener.com
Regeneron’s LAG-3 Inhibitor Fianlimab Flunks A Key Pipeline Test - Citeline News & Insights
Regeneron shares fall 12% on disappointing melanoma trial data By Investing.com - Investing.com Canada
BofA reiterates Regeneron stock rating after melanoma trial miss By Investing.com - Investing.com Canada
4 spaces primed for the next wave of gene therapies - BioSpace
Regeneron Stock Underperforms S&P 500 as Revenue Growth Slows | 2026 AnalysisNews and Statistics - IndexBox
Regeneron (REGN) Reports Phase 3 Trial Results for Melanoma Trea - GuruFocus
Leuthold Group LLC Increases Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
L & S Advisors Inc Makes New $3.59 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Dana Investment Advisors Inc. - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by ARS Investment Partners LLC - MarketBeat
Assessing Regeneron Pharmaceuticals (REGN) Valuation After Recent Share Pullback And Pipeline Expectations - simplywall.st
symbol__ Stock Quote Price and Forecast - CNN
Regeneron Pharmaceuticals Inc stock (US7739031091): earnings beat keeps biotech heavyweight in focus - AD HOC NEWS
Regeneron (REGN) Reports Phase 3 Trial Failure for Combination T - GuruFocus
Regeneron fails in study for Libtayo combo (REGN:NASDAQ) - Seeking Alpha
Regeneron’s drug combo fails to prove superiority over Merck’s Keytruda in melanoma - MSN
Lockheed Martin Investment Management Co. Invests $2.70 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Applied Finance Capital Management LLC Has $14.73 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron melanoma drug trial misses primary endpoint By Investing.com - Investing.com Canada
Regeneron’s Drug Combo Fails To Prove Superiority Over Merck’s Keytruda In Melanoma - Stocktwits
Regeneron Reviews Phase 3 Trial Results for Fianlimab - Intellectia AI
Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma - The Manila Times
UPDATENext Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair - The Manila Times
UPDATE – Next Generation of Scientific Leaders Awarded More - GlobeNewswire
Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair - The Manila Times
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):